Shares of Biogen (BIIB) are up $7.51, or 4% to $182.81 in pre-market trading after Novo Nordisk (NVO) announced that the 2-year primary analysis of evoke and evoke+ phase 3 trials in early-stage symptomatic Alzheimer’s disease did not confirm superiority of semaglutide versus placebo in the reduction of progression of Alzheimer’s disease.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BIIB:
- Biogen, Dayra Therapeutics enter research collaboration
- Biogen price target raised to $157 from $118 at Piper Sandler
- Biogen, Stoke Therapeutics announce publication of data from BUTTERFLY study
- Stoke Therapeutics, Biogen publish final data from BUTTERFLY study
- Biogen says CHMP adopts positive opinion on high dose regimen of nusinersen